Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof
CA 2002869 A1 · Owner: Bevilacqua, Michael P. · Inventors: Bevilacqua, Michael P.; Stengelin, Siegfried; Gimbrone, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to cloned genes or degenerate variants, thereof, which encode endothelial-leukocyte adhesion molecule-1 (ELAM- 1), or fragments thereof. Such fragments may be leukocyte or complement-binding. The invention also relates to cloned genes encoding fusion proteins comprising ELAM. The invention also relates to vectors containing the cloned genes of the invention hosts trans-, formed with the vectors, and the protein products expressed therefrom. The invention also relates to pharmaceutical compositions comprising the expressed proteins. The invention also relates to methods for the treatment of inflammation, post reperfusion injury bacterial infec-, tions, vasculitis, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 14, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 14, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 14, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.